ADARx Pharmaceuticals (ADRX) vs Biohaven (BHVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ADARx Pharmaceuticals is the larger company by market cap ($1.93 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | BHVN |
|---|---|---|
| Share price | $18.05 | $12.18 |
| Market cap | $1.93B | $1.84B |
| 1-day change | +2.12% | +2.10% |
| YTD return | — | +5.67% |
| 1-year return | — | -22.23% |
| EPS (TTM) | $-1.16 | $-4.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-738.82M |
| 52-week high | $23.21 | $18.57 |
| 52-week low | $16.64 | $7.48 |
| Distance from 52-week high | -22.23% | -34.40% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +74.63% |
| Average volume | 1.25M | 2.62M |
| Shares outstanding | 106.80M | 151.04M |
| Employees | 100 | 274 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
ADRX vs BHVN FAQ
Which is bigger, ADARx Pharmaceuticals or Biohaven?
ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.93B compared with $1.84B for Biohaven (BHVN).
Are ADARx Pharmaceuticals and Biohaven in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.